Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun(Canadian Institute for Advanced Research), René Bernards(The Netherlands Cancer Institute), Lodewyk F.A. Wessels(The Netherlands Cancer Institute), Jelle Wesseling(Leiden University Medical Center), Sebastijan Hobor(The Francis Crick Institute), Guus J.J.E. Heynen(Cancer Genomics Centre), Prashanth Kumar Bajpe(Cancer Genomics Centre), Sidong Huang(McGill University Health Centre), Alexander M.M. Eggermont(University Medical Center Utrecht), Wipawadee Grernrum(Cancer Genomics Centre), Anirudh Prahallad(Novartis (Switzerland)), Andreas Schlicker(Bayer (Germany)), Roderick L. Beijersbergen(The Netherlands Cancer Institute), Alberto Bardelli(IFOM), Stefan M. Willems(Heidelberg University), Stéphan Vagner(Institut Curie), Davide Zecchin(University College London), Cor Lieftink(Cancer Genomics Centre), Christian U. Blank(The Netherlands Cancer Institute), Liqin Wang(Nanjing Medical University), Caroline Robert(Institut Gustave Roussy), Ingrid Hofland(Cancer Genomics Centre), Federica Di Nicolantonio(Candiolo Cancer Institute), Christina Mateus(Institut Gustave Roussy), John B.A.G. Haanen(Leiden University Medical Center)
Cited by 913
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k